Search Results for "Colchicine And Rivaroxaban"

21:26 EST 10th February 2016 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

BMJ Investigation Casts Doubt on Validity of Rivaroxaban Trial

New questions have been raised about the validity and reliability of data in the ROCKET-AF trial, which serves as the backbone for the approval of rivaroxaban (Xarelto), according to an investigation ...

Gout: Colchicine Linked to Reduced CV Risk

Colchicine use was associated with a 49% lower risk for cardiovascular events and a 73% reduction in all-cause mortality in patients with gout. Medscape Medical News

VTE in Primary Care: Patient Management With Rivaroxaban

Get guidance on the practical use of rivaroxaban for the treatment of patients with VTE. British Journal of Cardiology

Japan approves rivaroxaban as treatment for thrombosis

Japan's Ministry of Health, Labor and Welfare has approved rivaroxaban, or Xarelto, for the secondary prevention and treatmen -More- 

Rivaroxaban: It's Not Time to Cut the Rope, Yet

The warfarin arm of the ROCKET AF trial used a faulty INR device, leading to calls for independent verification of the study. Dr Mandrola agrees but is reassured by the real-world data on rivaroxa...

ROCKET-AF: Rivaroxaban, Warfarin Similar for AF Plus Diabetes

More findings show similar safety and efficacy rates between the two treatments, whether or not AF patients also have diabetes, suggesting rivaroxaban may be a feasible alternative. Heartwire fr...

Low bleeding and stroke rates in AF patients given rivaroxaban for stroke prevention

(European Society of Cardiology) Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study p...

EU OKs rivaroxaban testing solution from Instrumentation Laboratory

HemosIL, a solution developed by Instrumentation Laboratory to test for rivaroxaban, has obtained CE mark approval from Europ -More- 

Matching PubMed Articles

Colchicine for prevention of cardiovascular events.

Colchicine is an anti-inflammatory drug that is used for a wide range of inflammatory diseases. Cardiovascular disease also has an inflammatory component but the effects of colchicine on cardiovascula...

Fatal intracerebral bleeding under rivaroxaban.

Rivaroxaban is a factor-Xa-inhibitor which has been shown to be non-inferior to the vitamin-K-antagonist (VKA) warfarin in atrial fibrillation patients. In the manufacturer-sponsored trial, the rate o...

Association of Rivaroxaban Anticoagulation and Spontaneous Vitreous Hemorrhage.

Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation. We describe a correlation between rivaroxaban and spontaneous vitreous hemorrhage.

In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.

Four-factor prothrombin complex concentrate (PCC) 50 iu/kg is able to swiftly restore haemostatic parameters in healthy subjects on rivaroxaban. We hypothesized that lower dosages of PCC may be suffic...

A high performance thin layer chromatographic method for the estimation of colchicine in different formulations.

Colchicine is a main alkaloid present in bitter and sweet variety of colchicum (Colchicum luteum Baker), which have been reported to possess anti-rheumatic, anti-gout, and anticancer potential. Colchi...

Search Whole site using Google

Quick Search
Advertisement Advertisement